Phase 3 Study of A Group A, C Polysaccharide Meningococcal and Type b Haemophilus Influenzal Conjugate Vaccine

PHASE3CompletedINTERVENTIONAL
Enrollment

900

Participants

Timeline

Start Date

April 30, 2012

Primary Completion Date

September 30, 2012

Study Completion Date

November 30, 2012

Conditions
MeningitisInfluenza
Interventions
BIOLOGICAL

A+C+hib Conjugate Vaccine

The group A, C polysaccharide meningococcal and type b haemophilus influenzal conjugate vaccine (Wuxi Royal Biological Co., LTD, 20110101) will be administered on one arm, intramuscularly, per 0.5ml dose

BIOLOGICAL

Placebo

Placebo will be administered intramuscularly on the other arm, intramuscularly, per 0.5ml dose

BIOLOGICAL

A+C Vaccine

The group A, C polysaccharide meningococcal vaccine (Yunnan Walvax Biotechnology Co., LTD, 20101202) will be administered intramuscularly on one arm, per 0.5ml dose

BIOLOGICAL

Hib vaccine

The type b haemophilus influenzal vaccine (Sanofi Pasteur Limited) will be administered intramuscularly on the other arm, per 0.5ml dose

Trial Locations (1)

Unknown

Funing county Center for Disease Control and Prevention, Yancheng

All Listed Sponsors
collaborator

Royal (Wuxi) Biological Co., LTD

OTHER

lead

Jiangsu Province Centers for Disease Control and Prevention

NETWORK

NCT01580033 - Phase 3 Study of A Group A, C Polysaccharide Meningococcal and Type b Haemophilus Influenzal Conjugate Vaccine | Biotech Hunter | Biotech Hunter